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Introduction Primary brain tumors comprise only approximately 2 % of all the malignant diseases. 1 However, the major data source -surveillance, epidemiology and end results(SEER) reported an incidence of 6.5 per 100000 persons. More than 17000 cases are diagnosed every year in the united states and among them approximately 13,000 die every year. 2 More specific CNS tumor types also differ in incidence rate based on anatomical location and also with age. 3 Gliomas constitute 40 percent of all primary CNS tumors. 4 Two third of gliomas are high grade, which comprises the glioblastoma multiforme (GBM), anaplastic astrocytoma (AA), anaplastic oligodendroglioma, anaplastic oligoastrocytoma and less commom varieties such as anaplastic ependymoma and anaplastic ganglioglioma. 5 Male to female ratio among affected patient is about 3:2 and most of the HGG are sporadic, although they are associated with genetic syndromes. 6, 7 e peak age of onset for anaplastic astrocytoma is during the 4th and 5 th decade, while GBM generally presented in the 6 th and 7 th decade. 8 ere are several presumed reasons for miserable outcome of high grade gliomas. First the tumor cells in GBM extensively infiltrate the surrounding brain parenchyma, thereby limiting the overall utility of surgical resection. Second the blood brain barrier is an obstacle to the adequate delivery of chemotherapy agents to brain tumors. 9 ird HGG is resistant to most cytotoxic agents, the expression of MGMT promoter methylation is thought to be the major mechanism of the resistance. 10 erefore surgical resections alone is the limitation in the treatment of HGG. 11 HGG have high morbidity and mortality rate, even with optimal, treatment median survival is only 12 to 15 months and 2 years survival rate in the range of only 8 to 12 percent for glioblastoma multiforme and 2 to 7 years for anaplastic astrocytoma. 12 Without any treatment the median survival is only 3 to 6 months from the time of diagnosis. 13 e standard management of HGG involve cytoreduction by surgical resection when feasible followed by radiation therapy with or without adjuvant chemotherapy. 13 Adjuvant radiation therapy helps to decrease local failure, delays recurrence and prolong survival up to 12 months. 14 Most recently, the effectiveness of this concomitant chemotherapy with Temozolomide has also been reported in many studies. e results of many trials demonstrated that concomitant radiation therapy plus continuous daily Temozolomide therapy followed by additional cycles of the standard regimen of adjuvant Temozolomide therapy is well tolerated and may prolong survival in patient with malignant glioma. 12 Temozolomide is very easy to administer and safe to handle and also produced by our domestic pharmaceuticals. Sixty patients with newly diagnosed & histologically proved high grade glioma with a age range of 18-70 and of both sexes years were enrolled as study population. All patients had a UICC performance status at and below 70. ey were divided in to two arms, Arm A and Arm B, and assigned to receive either radiation therapy alone (fractionated focal irradiation in daily fractions of 2 Gy in five fractions per week for six weeks, for a total 60 Gy -conventional) or radiation therapy plus Temozolomide (75 mg/m 2 from 1 st day of radiation therapy to last day of radiation therapyexperimental) followed by six cycles of adjuvant temozolomide (150 to 200mg per square meter for five days during each 28 day cycle).
Methods
Prior to treatment, evaluation of hematological, renal and hepatic functions was done and absolute neutrophil count >15/mL, platelet count > 100000 / mL, hemoglobin >10 gm/dl, serum creatinine and total serum bilirubin less than 1.5 times the upper limit of normal and AST less than twice the upper limit of normal were ensured. Poor general physical conditions were not taken into account. Pretreatment evaluation of tumor for planning and outcome prediction, computed tomography (CT), magnetic resonance imaging (MRI) was also done. Follow-up were done weekly & included included physical examination and full blood counts. Antiemetic prophylasix was also given before the initial doses of concomitant Temozolomide and was continued during the adjvant five days courses of temozolomide.
Toxic effects were graded according to the National Cancer Institute Common Toxicity Criteria, version 2.0, with a score of 1 indicating mild adverse effects, a score of 2 
Results
Haematological toxicities were compared between the patients of two arms. Patients treated by CCRT with Temozolomide showed more toxicities than the conventional radiation treatment alone in some stages. As a whole the differences were not significant.
rombocytopenia toxicity was compared in 11 different periods of time. At the beginning of the treatment all patients in both arms showed grade 0 toxicities. At day 7 of the treatment in Arm A, 1 patient reported with grade 1 thrombocytopenia toxicity in both arms. All other patients showed grade 0 thrombocytopenia toxicity. At day 14 of treatment 1 patient of Arm B showed grade 2 thrombocytopenia toxicity; at 21 days of the treatment 1 patient in arm B had grade 2 thrombocytopenia toxicity. At 28 days after treatment in arm A, one patient showed grade 1 thrombocytopenia toxicity and in arm B one patient had grade 2 thrombocytopenia toxicity. rombocytopenia toxicities after 1 st cycle to 3 rd cycle of TMZ treatment were identical in both arms i.e. all the patients showed grade 0 thrombocytopenia toxicities. After 4 th and 6 th cycles of TMZ treatment 1 patient in arm A showed grade 1 thrombocytopenia toxicity. Grade 0 thrombocytopenia toxicities were noted in 5 th cycle of TMZ in both arms. However, no differences of thrombocytopenia toxicities were statistically significant between these two arms (p>0.05). (Table-I) WBC toxicity is compared in 11 different periods of time. At day 7 of the treatment in Arm A, 1 patient reported with grade 1 WBC toxicity while all patients in Arm B showed Table-II) Hb% toxicity is compared in 11 different periods of time. At day 7 of the treatment in Arm A, 1 patient reported with grade 2 (Hb% 9.5-7.5gm/dl) toxicity while 1 patient in Arm B showed grade 1 (Hb% 11.5-9.5 gm/dl) toxicity. At day 14 and 21 of the treatment only 1 patient in arm B had grade 1 toxicity. At 28 days after treatment in arm A, four patients showed grade 1 and one patient showed grade 2 toxicities. However, in Arm B only one patient had grade 1 toxicity.
No statistically significant difference was observed between these two arms regarding Hb% toxicities. (Table-III) Discussion e mean age of the patients in arm A was 46.9 (SD ± 11.7) years and that of the arm B was 42.8 (SD ± 14.2) years. e age group distribution was almost identical which helped in minimizing bias. e other socio-demographic variables like socio-economic status, occupation or level education were not different across the two arms.
Headache and vomiting were the two main presenting complaints of the patients in both arms. More than 68% patients were suffering from glioblastoma multiforme and the rest were from anaplastic astrocytoma. All of the patients in Arm A tested positive for MGMT methylation test. Almost reverse findings was noted in arm B patients. Statistically this difference was highly significant (p<0.001).
rombocytopenia toxicity was also compared in several different periods of time starting from the beginning of the treatment to after 6 months of treatment completion. However, no differences of thrombocytopenia toxicities were statistically significant between these two arms (p>0.05).
Finally the treatment responses across the two arms were compared. In Arm A, 24 patients (80%) showed complete response and in Arm B, 20 patients (66.7%) showed complete response; partial responses were 2 (6.7%) and 4 (13.3%) in the two arms respectively. Progressive disease was noticed in 2 patients (6.7%) in each arm. Two patients (6.7%) in Arm A and 3 patients (10%) in Arm B came back with recurrence. One death (3.3%) was reported in conventional group i.e. in Arm B. Clinically this difference warrants much attention though statistical significance was not established in this regard.
